Yahoo · Oct 26, 2026
BHC Q3 Earnings Preview: Here's What You Should Know
Bausch Health reports Q3 2026 results on Oct. 28, with $2.75 billion in expected sales. Explore key segment drivers and mixed earnings surprise history.
HR
NASDAQ · HRMY
Harmony Biosciences Holdings, Inc.
Healthcare · Biotechnology
$38.76
Up+$0.17 (+0.44%)
Updated Nov 1, 2026, 8:02 PM
SID Score
7.9/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 2.28B
- P/E ratio
- 12.47
- Dividend yield
- 0.00%
- 52-week range
- $26.34 – $43.49
- Volume
- 871.47K
- Avg. volume
- 922.99K
Price performance · HRMY
HRMY price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
HRMY closed at $38.76 after 20 trading sessions, down 2.91% for the selected period.
- Last close
- $38.76
- Period change
- -2.91%
- Period low
- $36.03
- Period high
- $40.28
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $38.58 | $39.10 | $38.39 | $38.76 | 871.47K |
| Oct 29, 2026 | $38.65 | $39.20 | $38.04 | $38.59 | 778.85K |
| Oct 28, 2026 | $37.72 | $38.525 | $37.28 | $38.50 | 1M |
| Oct 27, 2026 | $36.90 | $37.98 | $36.62 | $37.95 | 736.93K |
| Oct 26, 2026 | $36.28 | $37.19 | $36.13 | $36.83 | 852.7K |
| Oct 23, 2026 | $36.11 | $37.05 | $35.00 | $36.13 | 2.31M |
| Oct 22, 2026 | $38.50 | $39.635 | $34.11 | $36.03 | 2.91M |
| Oct 21, 2026 | $38.58 | $38.93 | $38.13 | $38.31 | 1.06M |
| Oct 20, 2026 | $37.99 | $39.23 | $37.4901 | $38.70 | 798.59K |
| Oct 19, 2026 | $37.84 | $37.97 | $37.165 | $37.54 | 1.01M |
| Oct 16, 2026 | $38.47 | $39.00 | $37.85 | $37.95 | 892.27K |
| Oct 15, 2026 | $38.04 | $39.00 | $38.00 | $38.27 | 798.33K |
| Oct 14, 2026 | $37.16 | $38.31 | $36.92 | $37.51 | 972.24K |
| Oct 13, 2026 | $37.91 | $38.1725 | $35.99 | $37.03 | 1.42M |
| Oct 12, 2026 | $38.34 | $39.89 | $37.01 | $38.23 | 1.15M |
| Oct 9, 2026 | $39.53 | $40.57 | $39.5092 | $40.28 | 487.16K |
| Oct 8, 2026 | $39.14 | $39.89 | $38.6802 | $39.60 | 865.03K |
| Oct 7, 2026 | $39.27 | $39.86 | $39.095 | $39.34 | 547K |
| Oct 6, 2026 | $40.09 | $40.35 | $38.91 | $39.36 | 507.28K |
| Oct 5, 2026 | $39.76 | $40.77 | $39.51 | $39.92 | 897.92K |
Latest HRMY news
The latest Smart Investors Daily articles mentioning HRMY.
Stock researchCompany · Overview
Company
Market Activity
Research & News
HRMY research
Overview
Company profile and research snapshot.
Company profile
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $47.80
- Implied upside
- —
- Analysts
- 17
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 19, 2026 | Needham | Buy | — |
| Oct 13, 2026 | HC Wainwright & Co. | Buy | — |
| Oct 12, 2026 | Needham | Buy | — |
| Aug 26, 2026 | Wolfe Research | Outperform | — |
| Aug 5, 2026 | Truist Securities | Hold | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 22, 2026
HRMY or ARGX: Which Is the Better Value Stock Right Now?
HRMY vs. ARGX: Which Stock Is the Better Value Option?
Yahoo · Oct 22, 2026
Are Investors Undervaluing Harmony Biosciences (HRMY) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
SeekingAlpha · Oct 21, 2026
Harmony Biosciences: A Cash Machine With A Patent Ruling Hanging Over It
Harmony Biosciences' valuation is supported by WAKIX's robust performance, cash reserves, and limited downside. See why I rate HRMY stock a Buy.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
